WO2003077865A3 - Methods and compositions for directing cells to target organs - Google Patents

Methods and compositions for directing cells to target organs Download PDF

Info

Publication number
WO2003077865A3
WO2003077865A3 PCT/US2003/007836 US0307836W WO03077865A3 WO 2003077865 A3 WO2003077865 A3 WO 2003077865A3 US 0307836 W US0307836 W US 0307836W WO 03077865 A3 WO03077865 A3 WO 03077865A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mammal
compositions
target organs
directing cells
Prior art date
Application number
PCT/US2003/007836
Other languages
French (fr)
Other versions
WO2003077865A2 (en
Inventor
Catherine Phillips
Jr Julian P Breillatt
Original Assignee
Baxter Int
Baxter Healthcare Sa
Dept Of Veteran Affairs
Catherine Phillips
Jr Julian P Breillatt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Dept Of Veteran Affairs, Catherine Phillips, Jr Julian P Breillatt filed Critical Baxter Int
Priority to AU2003225793A priority Critical patent/AU2003225793A1/en
Publication of WO2003077865A2 publication Critical patent/WO2003077865A2/en
Publication of WO2003077865A3 publication Critical patent/WO2003077865A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.
PCT/US2003/007836 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs WO2003077865A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003225793A AU2003225793A1 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36449802P 2002-03-15 2002-03-15
US60/364,498 2002-03-15

Publications (2)

Publication Number Publication Date
WO2003077865A2 WO2003077865A2 (en) 2003-09-25
WO2003077865A3 true WO2003077865A3 (en) 2004-04-01

Family

ID=28041926

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/007934 WO2003105908A2 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
PCT/US2003/007836 WO2003077865A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs
PCT/US2003/007834 WO2003077864A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007934 WO2003105908A2 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007834 WO2003077864A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Country Status (10)

Country Link
US (8) US7282222B2 (en)
EP (1) EP1499347A2 (en)
JP (1) JP2006501169A (en)
KR (1) KR20050013531A (en)
CN (1) CN100579577C (en)
AU (4) AU2003267949A1 (en)
CA (1) CA2479309A1 (en)
HK (1) HK1079987A1 (en)
IL (1) IL164079A0 (en)
WO (3) WO2003105908A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA2430989A1 (en) 2000-12-06 2002-06-13 Robert J. Hariri Method of collecting placental stem cells
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2002063962A1 (en) * 2001-02-14 2002-08-22 Hariri Robert J Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
AU2003267949A1 (en) * 2002-03-15 2003-12-31 U.S. Government As Represented By The Department Of Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
US7576186B2 (en) * 2002-04-23 2009-08-18 Roger Williams Hospital Compositions and methods for stem cell delivery
US9321992B2 (en) * 2002-06-14 2016-04-26 Case Western Reserve University Cell targeting methods and compositions
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
CN1711475A (en) * 2002-10-10 2005-12-21 退伍军人事务部 Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
KR101042448B1 (en) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
US8603462B2 (en) 2003-04-01 2013-12-10 University Of Utah Research Foundation Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
EP2298861B1 (en) 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JP2008515434A (en) * 2004-10-08 2008-05-15 ジョージア テック リサーチ コーポレイション Microencapsulation of cells in hydrogels using electrostatic potential
FI20055398A0 (en) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Method for evaluating cell populations
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
JP5550235B2 (en) 2005-12-29 2014-07-16 アントフロゲネシス コーポレーション Placental stem cell population
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
EP2422794A3 (en) 2006-03-07 2013-03-13 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
CA2672998C (en) 2007-01-02 2013-08-06 University Of Central Florida Research Foundation, Inc. Methods and materials for stimulating proliferation of stem cells
FI20075030A0 (en) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Method of modifying cells
US20090104160A1 (en) * 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
CN103356711A (en) 2007-02-12 2013-10-23 人类起源公司 Immunomodulation using placental stem cells
EP2142206B1 (en) 2007-03-30 2014-07-30 The Cleveland Clinic Foundation SDF-1 for use in the treatment of ischemic peripheral vascular disorders
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2155860B1 (en) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
WO2009037690A1 (en) * 2007-09-19 2009-03-26 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8142759B2 (en) * 2007-12-12 2012-03-27 Institute Of Nuclear Energy Research Glyco-molecular imaging method for grade classification of liver fibrosis and its glyco-molecular imaging agent thereof
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
KR20180108887A (en) 2008-08-20 2018-10-04 안트로제네시스 코포레이션 Treatment of stroke using isolated placental cells
JP6169316B2 (en) 2008-08-20 2017-07-26 アンスロジェネシス コーポレーション Improved cell composition and method for producing the same
MX2011001992A (en) 2008-08-22 2011-03-29 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations.
SG190659A1 (en) 2008-09-02 2013-06-28 Pluristem Ltd Adherent cells from placenta tissue and use thereof in therapy
RU2562154C2 (en) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Amniotic adhesive cells
US10328103B2 (en) 2009-01-03 2019-06-25 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US8470308B2 (en) * 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
JP5856059B2 (en) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション SDF-1 delivery for treating ischemic tissue
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
ES2646750T3 (en) 2010-01-26 2017-12-15 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
WO2011102890A1 (en) * 2010-02-18 2011-08-25 Albert Einstein College Of Medicine Of Yeshiva University Methods of treatment of hemophilia
KR20190076060A (en) 2010-04-07 2019-07-01 안트로제네시스 코포레이션 Angiogenesis using placental stem cells
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
US20130156773A1 (en) * 2010-06-18 2013-06-20 Women And Infants Hospital Of Rhode Island Lung regeneration using cord blood-derived hematopoietic stem cells
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US8877207B2 (en) 2010-09-17 2014-11-04 University Of Central Florida Research Foundation, Inc. Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012127320A1 (en) 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
ES2707579T3 (en) 2011-06-01 2019-04-04 Celularity Inc Pain treatment using placental cytoblast
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
WO2015172659A1 (en) * 2014-05-14 2015-11-19 中国科学院上海生命科学研究院 Uses of il-17 in enhancing immune-suppression function of mesenchymal stem cells
WO2016057649A1 (en) * 2014-10-07 2016-04-14 NuTech Medical, Inc. Mesenchymal stem cell diagnostic testing
JP2018535655A (en) 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド ASGR inhibitor
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
MX2019011679A (en) 2017-04-01 2019-11-01 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy.
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466951A (en) * 1982-11-12 1984-08-21 University Of California Intracellular trapping of therapeutics or tracer agents
JPS61503003A (en) * 1984-04-19 1986-12-25 ユニバ−シテイ−　オブ　クイ−ンスランド Contraceptive methods, contraceptive preparations and contraceptive devices
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4801533A (en) * 1986-06-25 1989-01-31 Fudenberg H Hugh Method of using alpha-1 acid glycoprotein on T-cells as a marker for alzheimer's disease
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US5679323A (en) 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5342607A (en) * 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
EP0273452B1 (en) 1986-12-30 1994-03-23 Nihon Medi-Physics Co., Ltd. High molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilisation
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5098843A (en) * 1987-06-04 1992-03-24 Calvin Noel M Apparatus for the high efficiency transformation of living cells
US5270199A (en) * 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5128257A (en) * 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US4970154A (en) * 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5043260A (en) 1987-11-02 1991-08-27 Rhode Island Hospital Perfusion device with hepatocytes
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DK0452457T3 (en) 1989-11-03 1998-03-02 Univ Vanderbilt Method for in vivo removal of functional foreign genes
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
ZA922265B (en) * 1991-03-28 1992-12-30 American Cyanamid Co Somatostatin receptor
US5352670A (en) * 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
KR950014915B1 (en) * 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5545130A (en) * 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US5608060A (en) 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
US5616690A (en) * 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US5322682A (en) * 1992-08-06 1994-06-21 The Regents Of The University Of California Method for quantitatively measuring and mapping stored iron in tissue using MRI
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
ATE244888T1 (en) * 1993-02-05 2003-07-15 Epigen Inc HUMAN CARCINOMA ANTIGEN (HCA), HCA ANTIBODIES, HCA IMMUNOASSAYS, RECORDING METHODS AND THERAPY
US5670361A (en) 1993-05-17 1997-09-23 The Regents Of The University Of California HIV-specific ribozymes
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US5527884A (en) * 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5728399A (en) 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US5683866A (en) * 1996-05-09 1997-11-04 Sarkar; Debi P. Process for producing a targeted gene
US6146614A (en) * 1996-07-02 2000-11-14 Massachusetts Institute Of Technology Method for determining lymphocyte distribution and trafficking in mammals using imaging
US5719020A (en) 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
US7282220B1 (en) * 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
DE69842060D1 (en) 1997-05-08 2011-01-27 Oncothyreon Inc Method of obtaining activated T cells and antigen-incubated antigen-presenting cells
US6466599B1 (en) * 1999-04-07 2002-10-15 Lambda Physik Ag Discharge unit for a high repetition rate excimer or molecular fluorine laser
AU3923000A (en) * 1999-04-16 2000-11-02 Amgen, Inc. Agp-1 fusion protein compositions and methods
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
AU2003267949A1 (en) 2002-03-15 2003-12-31 U.S. Government As Represented By The Department Of Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
CN1711475A (en) * 2002-10-10 2005-12-21 退伍军人事务部 Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAMANO T. ET AL.: "Studies on the kinetics of hemopoietic stem cells and immune response to the Hapten-Carrier conjugate", THE JOURNAL OF IMMUNOLOGY, vol. 123, no. 3, September 1979 (1979-09-01), pages 1371 - 1375, XP002973618 *
NOMURA ET AL.: "Targeted gene delivery to the hepatocytes by asialoglycoprotein receptor-mediated endocytosis", ENVIRONMENTAL MEDICINE, vol. 39, no. 1, 1995, pages 17 - 20, XP002973620 *
PEREIRA R. ET AL.: "Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage and lung in irradiated mice", PROC. NATL. ACAD. SCI. USA, vol. 92, May 1995 (1995-05-01), pages 4857 - 4861, XP002139789 *
TERANISHI K. ET AL.: "Depletion of anti-gal antibodies in baboons by intravenous therapy with bovine serum albumin conjugated to gal oligosaccharides", TRANSPLANTATION, vol. 73, 15 January 2002 (2002-01-15), pages 129 - 139, XP002973619 *

Also Published As

Publication number Publication date
IL164079A0 (en) 2005-12-18
US7282222B2 (en) 2007-10-16
AU2003225791A8 (en) 2003-09-29
WO2003105908A3 (en) 2004-10-28
AU2003225793A8 (en) 2003-09-29
CA2479309A1 (en) 2003-12-24
US20060171934A1 (en) 2006-08-03
US20070243174A1 (en) 2007-10-18
US7563459B2 (en) 2009-07-21
US20070243173A1 (en) 2007-10-18
WO2003105908B1 (en) 2004-12-16
WO2003105908A2 (en) 2003-12-24
JP2006501169A (en) 2006-01-12
WO2003077865A2 (en) 2003-09-25
US20040180040A1 (en) 2004-09-16
US20100047215A1 (en) 2010-02-25
AU2003225791A1 (en) 2003-09-29
WO2003105908A9 (en) 2004-03-04
WO2003077864A2 (en) 2003-09-25
US20070196331A1 (en) 2007-08-23
WO2003077864A3 (en) 2004-04-01
AU2003267949A1 (en) 2003-12-31
AU2003225793A1 (en) 2003-09-29
EP1499347A2 (en) 2005-01-26
US20070243175A1 (en) 2007-10-18
US20070248577A1 (en) 2007-10-25
AU2009201808A1 (en) 2009-05-28
US20070110734A9 (en) 2007-05-17
CN1649621A (en) 2005-08-03
CN100579577C (en) 2010-01-13
KR20050013531A (en) 2005-02-04
HK1079987A1 (en) 2006-04-21

Similar Documents

Publication Publication Date Title
WO2003077865A3 (en) Methods and compositions for directing cells to target organs
NO20035637D0 (en) Carbon monoxide improves the results of tissue and organ transplants and suppresses apoptosis
WO2001078754A3 (en) Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
WO2004098535A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2007064846A3 (en) COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION
WO2004101758A3 (en) Composition for maintaining organ and cell viability
WO2002098897A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003105757A3 (en) Methods and compositions for milieu-dependent binding of a targeted agent to a target
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
IL206293A0 (en) Genetically engineered duckweed
EP1638460A4 (en) Directing cells to target tissues or organs
WO2007016501A3 (en) Compositions and method for brain specific targeted delivery of therapeutic agents
WO2006074012A3 (en) Facilitated cellular reconstitution of organs and tissues
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
WO2004006833A3 (en) Bowel cleansing composition
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
GB2415698A (en) Transformation of brassica
WO2005001044A3 (en) Compositions related to pleiotrophin methods and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP